Levodopa dispersible
DrugLevodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Other names: Madopar dispersible
NCT Number: NCT02769793
The purpose of this study is to determine whether levodopa/benserazide dispersible is effective in the adjunctive treatment of Parkinson's disease (PD) patients with delayed ON.
Looking for future studies?
Notify Me31 year–80 year
All sexes
Interventional
Phase 4
SMG-SNU Boramae Medical Center, Seoul, South Korea
Delayed ON is one of the motor complications of advanced PD patients that effect of anti-parkinsonian medication is delayed more than 40 minutes after intake. In the most severe cases, the effect does not appear even until next medication schedule, so called "No ON" status. It is important to manage delayed ON properly because it can interfere motor functions and quality of life of PD patients.
Levodopa/benserazide dispersible can be absorbed rapidly in the intestine, so theoretically it can break the poor response to conventional treatment of PD patients with delayed ON. However, this has not been proven by clinical trials till now.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Other names: Madopar dispersible
Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Other names: Madopar
Time frame: 4 weeks
A specialized 3-day PD diary will be distributed to the patients 3 days prior to each visit. This diary will evaluate the latency of ON after intake of the study medication.
Time frame: 4 weeks
a scale for assessment of parkinsonian symptom severity in PD patients
Time frame: 4 weeks
a scale for assessment of levodopa-induced dyskinesia in PD patients
Time frame: 4 weeks
a scale for activity of daily living assessment
Time frame: 4 weeks
a scale for health-related quality of life in PD patients
Time frame: 4 weeks
patient-centered assessment of global improvement
Time frame: 4 weeks
clinician's assessment for global improvement
Time frame: 4 weeks
global cognition assessment
Time frame: 4 weeks
a severity assessment index for PD patients with motor fluctuation
Time frame: at baseline and after 4 weeks of each treatment arm
whether delayed ON and treatment response are affected by H.pylori status
Seoul National University Hospital
Other
Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06133283
Basal Ganglia Diseases, Brain Diseases
San Antonio, Texas, United States
View Trial DetailsNCT05766813
Basal Ganglia Diseases, Brain Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07723027
Basal Ganglia Diseases, Brain Diseases
Shakargarh, Punjab Province, Pakistan
View Trial DetailsNCT07361250
Basal Ganglia Diseases, Brain Diseases
Wuhan, Hubei, China
View Trial Details